Genmab — Oktober 2017
-
Celgene is down 15% in premarket!
-
Celgene is down 31% since 2nd October!
-
...det kan ikke rigtigt betale sig at skuffe forventningerne... Auch!
-
IBB on TL support , will it hold? https://twitter.com/EgidiusLambrech/status/923544976822239234
-
it seems that FY revlimid guidance remains unchanged at 8b-8,3b. Remarkable considering the 20% price hike....
-
Kunne godt tænke mig, at vi satte lidt fokus på analytikernes rolle og funktion. Tænker de ofte vurderer tingene "forkert", og så skuffes markedet, når de reelle tal kommer. Tillægges analytikernes vurderinger, og dermed dagskursen, en for høj vægt i f.h.t virkelighedens virkelighed?
-
bankanalytikerne har da været mere forsigtige end prognoser her på chatten!
-
ofte er bankanalytikere her blevet beskyldt for at være alt for conservative
-
Genmabs egne meget forsigtige
prognoser ser ud til at ramme plet -
mon ikke det er JJ's prognoser? GEN har vist aldrig præsteret en nøjagtig prognose...
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind